Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023 is a research paper published in Influenza and Other Respiratory Viruses (2024). On theSindex it has a DataRank of 0.385. It has been cited 12 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: UL1TR001857
NCI NIH HHS
Grant: R01 CA262015
NCIRD CDC HHS
Grant: U01 IP001180
NCIRD CDC HHS
Grant: U01 IP001181
NCIRD CDC HHS
Grant: U01 IP001182
NCIRD CDC HHS
Grant: U01 IP001184
NCIRD CDC HHS
Grant: U01 IP001189
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001180-01
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001184-01
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001194-01
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001182-01
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001193-01
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001191-01
Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
ACL HHS
Grant: U01IP001191
ACL HHS
Grant: U01IP001193
ACL HHS
Grant: U01IP001194
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001181-01
RFA-IP-22-004, CORVETS - Cleveland Ohio Respiratory Viruses Vaccines Effectiveness across Traditional Risk Factors and Social Determinants of Health
US Centers for Disease Control and Prevention Cooperative Agreement
Grant: 1 U01 IP001189-01
National Institutes of Health
Grant: 5U01IP001184-04
RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system
National Institutes of Health
Grant: 5U01IP001193-03
RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
National Institutes of Health
Grant: 5U01IP001189-02
RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).
National Institutes of Health
Grant: 3UL1TR001857-07S1
University of Pittsburgh Clinical and Translational Science Institute
National Institutes of Health
Grant: 5U01IP001194-04
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
National Institutes of Health
Grant: 5U01IP001182-02
RFA-IP-22-004, Multidisciplinary Approach to Understanding Vaccine Efficacy and Transmission of Viral Respiratory Tract Infections in the Real World
National Institutes of Health
Grant: 5U01IP001180-02
RFA-IP-22-004, Platform to Assess Influenza and COVID-19 Vaccine Effectiveness in Underserved Arizona Populations
Centers for Disease Control and Prevention
CDC HHS
FWCI
3.42
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals